We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Biosimilar User Fee Program Reflects PDUFA, Includes SPA Path
Biosimilar User Fee Program Reflects PDUFA, Includes SPA Path
December 9, 2011
The FDA’s proposed biosimilars user fee program mirrors that for drugs under the Prescription Drug User Fee Act (PDUFA), and includes performance goals for special protocol assessments (SPA) that could help ensure a clear path to approval for the generic biologics, the agency said Tuesday.